Nanosuspension Preparation via Solvent Exchange
Solution Overview
Problem
Pharmaceutically active compounds like triamcinolone exhibit poor solubility in aqueous media, leading to low bioavailability due to their poor solubility, which can be addressed by reducing particle size and increasing surface area.
Innovation Solution
A process for preparing an optically clear nanoparticulate suspension by dissolving a pharmaceutically active compound in a first solvent and introducing it into a second solvent, such as an aqueous medium, without using surfactants or mechanical shear, resulting in particles of desired size for enhanced bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods using surfactants and mechanical shear are used to reduce particle size, then bioavailability is improved, but formulation complexity and potential harmful effects increase
Solution Approach 1:
The patent removes surfactants and mechanical shear from the formulation process, extracting the harmful elements while retaining the beneficial particle size reduction through pure dissolution and precipitation mechanisms
Solution Approach 2:
The patent replaces mechanical shear forces with a chemical dissolution-precipitation process, substituting mechanical particle size reduction with a chemical mechanism that achieves the same therapeutic effect without mechanical complexity
2Reliability
If surfactants are used to enhance solubility and reduce particle size, then bioavailability is improved, but harmful effects and formulation complexity increase
Solution Approach 1:
The patent extracts and eliminates surfactants from the formulation, removing the source of harmful effects while maintaining particle size reduction through alternative dissolution-precipitation mechanisms
Solution Approach 2:
The patent converts the natural precipitation process into a beneficial mechanism, where the phase separation between organic and aqueous solvents automatically produces nanoscale particles without requiring harmful surfactants
3Reliability
If mechanical shearing is used to reduce particle size, then bioavailability is improved, but process complexity and energy consumption increase
Solution Approach 1:
The patent replaces energy-intensive mechanical shearing with a low-energy chemical dissolution and precipitation process, achieving particle size reduction through thermodynamic phase separation rather than mechanical force
Solution Approach 2:
The patent changes the physical-chemical parameters of the system by controlling temperature, solvent polarity, and concentration gradients to drive spontaneous nanoscale particle formation without mechanical energy input
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces a nanoparticulate suspension with increased bioavailability and optical clarity, achieving particle sizes between 100 nm to 1000 nm without relying on surfactants or mechanical shearing, thereby improving the absorption rate of the drug.
Implementation Method 1
combining a pharmaceutically active compound in a first solvent
Implementation Method 2
introduced into a second solvent which may then promote active compound precipitation
Data Source
AI summary
The present disclosure is directed at a pharmaceutically active nanoparticle suspension that may be optically clear. Such suspensions may be formed by selective dissolution of a pharmaceutically active compound in a first solvent followed by introduction into a second solvent, such as an aqueous medium, without substantial use of surfactants and/or mechanical shear.



